<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(42)</volume><submitter>Pradeep Kumar M</submitter><pubmed_abstract>Breast cancer continues to pose a major worldwide health concern, characterized by its complexity and the diverse nature of its molecular subtypes. Among these, triple-negative breast cancers (TNBCs) present a formidable obstacle due to their aggressive progression and lack of targeted hormonal therapies. Molecular hybridization is a compelling strategy in drug design and development, combining distinct bioactive components to enhance potency and selectivity. Herein, we present the design and synthesis of a new series of pyrido-indole-one hybrids featuring a β-carboline core, by utilizing the molecular hybridization strategy, integrating indole-2-carboxamides with ynone functionalities to mitigate TNBC progression. A novel synthetic approach has been devised for synthesizing hybrid molecul</pubmed_abstract><journal>RSC advances</journal><pagination>35445-35459</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12461553</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pyrido-indole-one hybrids as potential anticancer agents against breast carcinoma: development of Ru(ii)-catalyzed annulation of indole-2-carboxamides, biological screening and molecular docking studies.</pubmed_title><pmcid>PMC12461553</pmcid><pubmed_authors>Nagendra Babu B</pubmed_authors><pubmed_authors>Sharma N</pubmed_authors><pubmed_authors>Sai Balaji A</pubmed_authors><pubmed_authors>Sarkar T</pubmed_authors><pubmed_authors>Kumar B H</pubmed_authors><pubmed_authors>Durga Prasad V</pubmed_authors><pubmed_authors>Pradeep Kumar M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pyrido-indole-one hybrids as potential anticancer agents against breast carcinoma: development of Ru(ii)-catalyzed annulation of indole-2-carboxamides, biological screening and molecular docking studies.</name><description>Breast cancer continues to pose a major worldwide health concern, characterized by its complexity and the diverse nature of its molecular subtypes. Among these, triple-negative breast cancers (TNBCs) present a formidable obstacle due to their aggressive progression and lack of targeted hormonal therapies. Molecular hybridization is a compelling strategy in drug design and development, combining distinct bioactive components to enhance potency and selectivity. Herein, we present the design and synthesis of a new series of pyrido-indole-one hybrids featuring a β-carboline core, by utilizing the molecular hybridization strategy, integrating indole-2-carboxamides with ynone functionalities to mitigate TNBC progression. A novel synthetic approach has been devised for synthesizing hybrid molecul</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-03T22:56:51.325Z</modification><creation>2026-05-02T03:12:01.156Z</creation></dates><accession>S-EPMC12461553</accession><cross_references><pubmed>41019818</pubmed><doi>10.1039/d5ra06548h</doi></cross_references></HashMap>